HC Wainwright Has Negative Estimate for TYRA FY2024 Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Tyra Biosciences in a note issued to investors on Monday, November 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($1.59) for the year, down from their prior estimate of ($1.53). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2024 earnings at ($0.52) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.17) EPS.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01).

Several other research analysts have also recently weighed in on TYRA. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. Piper Sandler began coverage on Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price on the stock. Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Finally, Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $31.00.

Tyra Biosciences Trading Down 1.3 %

TYRA stock opened at $15.74 on Wednesday. Tyra Biosciences has a 12-month low of $10.60 and a 12-month high of $29.60. The stock has a market cap of $796.44 million, a price-to-earnings ratio of -9.78 and a beta of 1.08. The business’s 50-day moving average is $21.51 and its 200 day moving average is $19.98.

Hedge Funds Weigh In On Tyra Biosciences

Several large investors have recently bought and sold shares of TYRA. HighVista Strategies LLC acquired a new position in Tyra Biosciences in the second quarter valued at $257,000. Valence8 US LP acquired a new position in Tyra Biosciences in the third quarter valued at $310,000. SG Americas Securities LLC acquired a new position in Tyra Biosciences in the third quarter valued at $311,000. The Manufacturers Life Insurance Company acquired a new position in Tyra Biosciences in the third quarter valued at $333,000. Finally, Rhumbline Advisers boosted its stake in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after acquiring an additional 2,574 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the transaction, the director now owns 458,506 shares in the company, valued at approximately $7,592,859.36. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the transaction, the director now owns 458,506 shares in the company, valued at approximately $7,592,859.36. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Todd Harris sold 19,084 shares of the company’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $27.90, for a total transaction of $532,443.60. Following the completion of the transaction, the chief executive officer now owns 1,355,927 shares of the company’s stock, valued at $37,830,363.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 101,050 shares of company stock valued at $2,235,492. 15.40% of the stock is currently owned by company insiders.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.